These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N; Tocci G; Ferri C High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]
5. Do PCSK9 inhibitors reduce cardiovascular events? Kolber MR; Nickonchuk T; Turgeon R Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099 [No Abstract] [Full Text] [Related]
6. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863 [TBL] [Abstract][Full Text] [Related]
7. CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors. Blind E; de Graeff PA; Meurs I; Holtkamp F; Baczynska A; Janssen H Eur Heart J; 2016 Feb; 37(6):502-3. PubMed ID: 26853264 [No Abstract] [Full Text] [Related]
8. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection. Lüscher TF Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743 [No Abstract] [Full Text] [Related]
9. PCSK9 Inhibitors: From Innovation to Sustainable Clinical Application. Lekuona I Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):996-998. PubMed ID: 30150140 [No Abstract] [Full Text] [Related]
10. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. Everett BM; Smith RJ; Hiatt WR N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323 [No Abstract] [Full Text] [Related]
11. [PCSK9 Inhibitors - the magic bullet for LDL cholesterol reduction?]. Richter K; Barthel A; Bornstein SR; El-Armouche A; Wagner M Dtsch Med Wochenschr; 2016 Jun; 141(12):863-9. PubMed ID: 27305302 [TBL] [Abstract][Full Text] [Related]
12. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848 [No Abstract] [Full Text] [Related]
14. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors? Bittner V Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023 [No Abstract] [Full Text] [Related]
15. The year in cardiology 2015: prevention. Chapman MJ; Blankenberg S; Landmesser U Eur Heart J; 2016 Feb; 37(6):510-9. PubMed ID: 26726043 [No Abstract] [Full Text] [Related]
16. New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors. Klug EQ; Raal FJ S Afr Med J; 2020 Oct; 110(11):13126. PubMed ID: 33403972 [No Abstract] [Full Text] [Related]
17. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
18. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels. Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965 [TBL] [Abstract][Full Text] [Related]
19. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]